At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
01952 EVEREST MED
Closed 04-22 16:08:30
38.820
-0.840
-2.12%
High39.640Low38.080Vol2.83M
Open39.460D1 Closing39.660Amplitude3.93%
Mkt Cap13.74BTradable Cap13.74BTotal Shares354.00M
T/O109.82MT/O Rate0.80%Tradable Shares354.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Everest MED Shares Climb Over 4% in Morning Session on AACR Data Release
Stock News  ·  04-21 09:40
Everest MED Shares Climb Over 4% in Morning Session on AACR Data Release
EVEREST MED Adds 3,250 Shares in March; New 2026 Equity Scheme Opens 35.36 Million-Share Mandate
Bulletin Express  ·  04-09
EVEREST MED Adds 3,250 Shares in March; New 2026 Equity Scheme Opens 35.36 Million-Share Mandate
BRIEF-Everest Medicines Says Aggregate Consideration Under Share Purchase Agreement Is $250 Million
Reuters  ·  04-08
BRIEF-Everest Medicines Says Aggregate Consideration Under Share Purchase Agreement Is $250 Million
EVEREST MED Forges Acquisition Pact with Hisun Biopharm to Broaden Asia-Pacific Commercial Footprint
Stock News  ·  04-08
EVEREST MED Forges Acquisition Pact with Hisun Biopharm to Broaden Asia-Pacific Commercial Footprint
Everest Med Plans US$250 Million Acquisition of Hasten’s Singapore Unit to Broaden APAC Chronic-Disease Portfolio
Bulletin Express  ·  04-08
Everest Med Plans US$250 Million Acquisition of Hasten’s Singapore Unit to Broaden APAC Chronic-Disease Portfolio
Everest Medicines signs deal to buy Hasten Biopharmaceuticals SG for US$250 million
Reuters  ·  04-08
Everest Medicines signs deal to buy Hasten Biopharmaceuticals SG for US$250 million
Everest Medicines - Unit to Buy Entire Equity Interest in Hasten Biopharmaceuticals (SG) Pte
THOMSON REUTERS  ·  04-08
Everest Medicines - Unit to Buy Entire Equity Interest in Hasten Biopharmaceuticals (SG) Pte
Everest Medicines - Aggregate Consideration Under Share Purchase Agreement Is US$250 Mln
THOMSON REUTERS  ·  04-08
Everest Medicines - Aggregate Consideration Under Share Purchase Agreement Is US$250 Mln
Everest Medicines' Substantial Shareholder Boosts Stake
MT Newswires Live  ·  03-30
Everest Medicines' Substantial Shareholder Boosts Stake
Major Shareholder Fu Wei Increases Stake in Everest Med by 860,000 Shares
Stock News  ·  03-30
Major Shareholder Fu Wei Increases Stake in Everest Med by 860,000 Shares
BRIEF-Everest Medicines Says Honorary Chairman Purchases 860,000 Shares For HK$32.7 Million On March 27
Reuters  ·  03-30
BRIEF-Everest Medicines Says Honorary Chairman Purchases 860,000 Shares For HK$32.7 Million On March 27
Everest Medicines - Chairman Purchases 860,000 Shares for HK$32.7 Mln at HK$38.12 per Share on March 27
THOMSON REUTERS  ·  03-30
Everest Medicines - Chairman Purchases 860,000 Shares for HK$32.7 Mln at HK$38.12 per Share on March 27
Stock Track | EVEREST MED Soars 9.80% Intraday on Strong Annual Results with 142% Revenue Growth and First-Time Profitability
Stock Track  ·  03-27
Stock Track | EVEREST MED Soars 9.80% Intraday on Strong Annual Results with 142% Revenue Growth and First-Time Profitability
EVEREST MED Shares Surge Over 8% in Morning Session on Strong Nefecon Sales and 142% Revenue Growth
Stock News  ·  03-27
EVEREST MED Shares Surge Over 8% in Morning Session on Strong Nefecon Sales and 142% Revenue Growth
Stock Track | Everest Medicines Plummets 5% Intraday Following Annual Net Loss Report
Stock Track  ·  03-26
Stock Track | Everest Medicines Plummets 5% Intraday Following Annual Net Loss Report
EVEREST MED Reports Fiscal Year Performance with 141.51% Revenue Surge Driven by Strong Nefecon® Sales
Stock News  ·  03-26
EVEREST MED Reports Fiscal Year Performance with 141.51% Revenue Surge Driven by Strong Nefecon® Sales
Everest Medicines FY2025 net loss narrows to RMB298 million; revenue more than doubled to RMB1.7 billion
Reuters  ·  03-26
Everest Medicines FY2025 net loss narrows to RMB298 million; revenue more than doubled to RMB1.7 billion
Everest Medicines Ltd - Net Loss for Year RMB297.8 Mln
THOMSON REUTERS  ·  03-26
Everest Medicines Ltd - Net Loss for Year RMB297.8 Mln
EVEREST MED Shares Surge Nearly 7% After Acquiring Greater China Rights to PSVT Drug
Stock News  ·  03-24
EVEREST MED Shares Surge Nearly 7% After Acquiring Greater China Rights to PSVT Drug
BRIEF-Everest Medicines Says Unit To Buy Assets For Up To $50 Million
Reuters  ·  03-23
BRIEF-Everest Medicines Says Unit To Buy Assets For Up To $50 Million

Introduction

Company Name.
EVEREST MED
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
Everest Medicines Ltd is a biopharmaceutical company primarily engaged in the discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines. The Company has built a product pipeline across renal, anti-infective, and autoimmune diseases. The Company’s products portfolio includes Nefecon (TARPEYO) using in the renal therapeutic area, XERAVA (eravacycline) using in the treatment of infections caused by susceptible gram-positive, gram-negative and anaerobic pathogens including those multidrug resistant isolates and other products. The Company conducts its business in the domestic and overseas markets.
Issue price:
--